| Supporting independent living and preventing isolation in adults of working age with social care needs | Quality standard |
| Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [TSID12183] | Technology appraisal guidance |
| Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments [ID6413] | Technology appraisal guidance |
| Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460] | Technology appraisal guidance |
| Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191] | Technology appraisal guidance |
| Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] | Technology appraisal guidance |
| Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918] | Technology appraisal guidance |
| The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound | Medical technologies guidance |
| Thyroid disease | Quality standard |
| Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tinnitus | Quality standard |
| Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122] | Technology appraisal guidance |
| Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064] | Technology appraisal guidance |
| Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217] | Technology appraisal guidance |
| Tirzepatide for treating type 2 diabetes in people 10 to 17 years
[TSID12131] | Technology appraisal guidance |
| Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683] | Technology appraisal guidance |
| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157] | Technology appraisal guidance |
| Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158] | Technology appraisal guidance |
| Tocilizumab for treating systemic sclerosis [ID1396] | Technology appraisal guidance |
| Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406] | Technology appraisal guidance |
| Tovorafenib for Glioma (rare disease) [TSID12140] | Technology appraisal guidance |
| Trans-venous embolisation for the treatment of Cerebrospinal fluid venous fistula (CSFVF) a cause of spontaneous intracranial hypotension (SIH) | Interventional procedures guidance |
| Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509] | Technology appraisal guidance |
| Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [TSID11910] | Technology appraisal guidance |
| Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511] | Technology appraisal guidance |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226] | Technology appraisal guidance |
| Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [TSID12104] | Technology appraisal guidance |
| Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540] | Technology appraisal guidance |
| Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772] | Technology appraisal guidance |
| Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891] | Technology appraisal guidance |
| Troriluzole for spinocerebellar ataxia [ID6456] | Technology appraisal guidance |
| Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402] | Technology appraisal guidance |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781] | Technology appraisal guidance |
| UX111 for treating mucopolysaccharidosis type IIIA [ID6540] | Technology appraisal guidance |
| Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806] | Technology appraisal guidance |
| Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] | Technology appraisal guidance |
| Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879] | Technology appraisal guidance |
| Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295] | Technology appraisal guidance |
| Vilobelimab for treating COVID 19 [TSID11815] | Technology appraisal guidance |
| Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807] | Technology appraisal guidance |
| Vulnerable populations: strategies for tackling inequalities | Quality standard |
| WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467] | Technology appraisal guidance |
| Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765] | Technology appraisal guidance |